linjc16/ctgov huggingface dataset:
Cerebral Hemodynamics During Early Verticalization After (Successful) Thrombectomy Poststroke

Study Overview
=================
Brief Summary
-----------------
This is a proof-of-concept study with a prospective observational design, where the association between progressive levels of verticalization and cerebral blood flow velocity (Ultrasound) in subacute stroke patients and healthy subjects will be investigated.

Official Title
-----------------
Cerebral Hemodynamics During Early Verticalization After (Successful) Thrombectomy Poststroke

Conditions
-----------------
Stroke, Healthy

Intervention / Treatment
-----------------
* Procedure: Verticalization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: First-ever ischemic stroke in the territory of the middle cerebral artery (MCA) ≤12 hours after mechanical thrombectomy Conscious Hemodynamically stable 18 years or older Informed consent of the patient and/ or legal representative Exclusion Criteria: Verticalization not allowed according to treating physician Known pre-stroke disease affecting cerebral blood flow Temporal bone windows insufficient to enable ultrasound penetration Intubation anticipated or occurred Venous thromboembolism Symptomatic intracranial hemorrhage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stroke subjects<br> | Procedure: Verticalization<br>* Progressive levels of verticalization<br>|
| Healthy<br> | Procedure: Verticalization<br>* Progressive levels of verticalization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood flow velocity | Cerebral blood flow velocity measured with transcranial doppler ultrasound | within 12 hours post thrombectomy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure | Systolic and Diastolic pressure | within 12 hours post thrombectomy | 
| Heart rate | Number of contractions (beats) of the heart per minute | within 12 hours post thrombectomy | 
| Oxygen saturation | Relative measure of the concentration of oxygen in the blood | within 12 hours post thrombectomy | 
| Impairment caused by a stroke | National Institutes of Health Stroke Scale - NIHSS (Maximum score 42 - higher scores mean a worse outcome) | within 12 hours post thrombectomy | 
| Neurological status | Glasgow Coma Scale - GCS (Maximum score 15 - higher scores mean a better outcome) | within 12 hours post thrombectomy | 
| Adverse events | headache, focal edema, seizures, hemorrhagic transformation | within 12 hours post thrombectomy |
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects

Study Overview
=================
Brief Summary
-----------------
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged > 18 years

Official Title
-----------------
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Surface Antigen, Inactivated, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years of age or older Exclusion Criteria: any serious disease such as cancer, autoimmune disease, advanced arteriosclerotic disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD) that requires oxygen therapy, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure and bleeding diathesis or conditions associated with prolonged bleeding time hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine known or suspected (or high risk of developing) impairment/alteration of immune function within the past 7 days, any acute disease or infections requiring systemic antibiotic or antiviral therapy fever within the past 3 days.No women in breast feeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Biological: Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008<br>* seasonal influenza vaccine 15ug<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and immunogenicity of seasonal inactivated, influenza vaccine, formulation 2007-2008, when administered to non-elderly adult and elderly subjects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adjuvanted Influenza Vaccine
12-month Study of AMG 073 in Renal Osteodystrophy

Study Overview
=================
Brief Summary
-----------------
4 doses of AMG 073 or placebo over 52 weeks after a 30-day screening period. Throughout the study, labs will be drawn to measure analytes such as iPTH and corrected calcium. In addition, a bone biopsy will be performed at screening and at the end of study.

Official Title
-----------------
A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism

Conditions
-----------------
Renal Osteodystrophy

Intervention / Treatment
-----------------
* Drug: AMG 073
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age of greater Using effective contraceptive measures iPTH greater than or equal to 300 pg/mL Serum Calcium greater than or equal to 8.4 mg/dL; Hemoglobin greater than 9 Stable hemodialysis for 1 month prior to day 1 Exclusion Criteria: Any unstable medical condition Pregnant or nursing women Recent parathyroidectomy Change in Vitamin D therapy Recent MI, Seizure, Malignancy, GI Disorder Inability to swallow tablets

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AMG 073<br> | Drug: AMG 073<br>* 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effects of AMG 073 compared with placebo on renal osteodystrophy as assessed by bone histomorphometry |  | entire study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effects of AMG 073 compared with placebo on intact parathyroid hormone (iPTH), bone-specific alkaline phosphatase (BALP), serum N-Telopeptide (N-Tx), and calcium x phosphorus product concentrations |  | entire study | 
| To evaluate the feasibility of measuring physical activity with accelerometry |  | entire study | 
| To evaluate the safety and tolerability of AMG 073 compared with placebo |  | entire study |
Cardiogenomics Registry

Study Overview
=================
Brief Summary
-----------------
This is a continuous blood banking study that will archive plasma and blood permitting DNA and plasma analysis at a future date. Subjects are recruited at the time of a clinically required procedure and blood samples are collected and banked and used for future research. The main purpose of this study is to investigate the interaction of multiple phenotypes and genotypes and their impact on cardiovascular disease events and measures of atherosclerosis progression.

Official Title
-----------------
CAD Genotype and Phenotype Cardiac Catheterization Laboratory Registry

Conditions
-----------------
Cardiovascular Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 17 years of age Undergoing a clinical required cardiovascular procedure Agree to donation of blood sample Provide written informed consent and Authorization for Use/Disclosure of PHI Exclusion Criteria: < 18 years of age Refusal to donate a blood sample Refusal to provide written informed consent and Authorization for Use/Disclosure of PHI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the relationship of multiple phenotypes and genotypes with cardiovascular disease |  | Yearly | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the impact of phenotypes and genotypes of specific patient subgroups (gender, ethnic, family history) on cardiovascular disease |  | Yearly | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiovascular
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Study Overview
=================
Brief Summary
-----------------
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce. The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Detailed Description
-----------------
Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of hypertension AE related to PARPi.

Official Title
-----------------
Arterial Hypertension With PARP Inhibitors in Cancer Patients: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database (ArteRIB)

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction, patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60), veliparib, pamiparib, fluzoparib (none). Exclusion Criteria: -chronology not compatible between the PARPi and adverse event
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| parp inhibitors<br>All patients treated at least with 1 PARPi | Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib<br>* All patients treated at least with 1 PARPi (alone or in combination)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hypertension reports related to PARPi. | Identification of the hypertension adverse event related to PARP inhibitors reported in the World Health Organization's (WHO) database of individual safety case reports. | From inception to 16 Feb, 2023 |
Impact of Antimicrobial Stewardship Programs in the Global Setting

Study Overview
=================
Brief Summary
-----------------
Antimicrobial resistance is one of the greatest threats to human health, and is driven by inappropriate antimicrobial use. Antimicrobial stewardship programs (ASPs) improve the use of antimicrobials in hospitals. The purpose of this study is to identify the need for and barriers to implementation of ASPs in three hospitals in Sri Lanka, Kenya, and Tanzania.

Detailed Description
-----------------
Antimicrobial resistance is one of the greatest threats to human health, and is driven by the inappropriate antimicrobial use. Antimicrobial stewardship programs (ASPs) improve the use of antimicrobials. The purpose of this study is to identify the need for and barriers to implementation of ASPs in three hospitals in Sri Lanka, Kenya, and Tanzania. The impact of creating a basic ASP will be assessed at each hospital.

Official Title
-----------------
Partnership to Enhance Antimicrobial Use in Resource-Limited Settings (PEARL): An Assessment of Need and Feasibility of Antimicrobial Stewardship Programs

Conditions
-----------------
Resistance Bacterial

Intervention / Treatment
-----------------
* Other: Antimicrobial stewardship advice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to the medical wards - Exclusion Criteria: None -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appropriate antimicrobial use, for example for urinary syndromes | A composite outcome will be created for 'inappropriate' antibiotic use. This outcome will consist of 1) Unnecessary treatment for asymptomatic bacteriuria, 2) Inappropriate duration of therapy for urinary tract infection (UTI)/ cystitis/ pyelonephritis (binary outcome- yes/no), and 3) Unnecessary double coverage for UTI/ cystitis/ pyelonephritis (binary outcome- yes/no) | 6 months |
Vaginal Misodel® in Comparison With Orally Administrated Misoprostol (Cytotec®) at Induction of Labour

Study Overview
=================
Brief Summary
-----------------
The study will compare orally administrated solution of Misoprostol (Cytotec®) with vaginal slow release (7ug/h) Misoprostol (Misodel®) regarding efficacy and safety during labour.

Detailed Description
-----------------
To compare orally administrated solution of misoprostol (Cytotec®) with vaginal slow release misoprostol (Misodel®) regarding efficacy and safety during labour Design: Randomised controlled trial (RCT) Settings: Obstetric departments of Sodersjukhuset, Stockholm Obstetric departments of Women's clinic, Karlstad.

Official Title
-----------------
Vaginal Misodel® in Comparison With Orally Administrated Misoprostol (Cytotec®) at Induction of Labour

Conditions
-----------------
Induced Deliveries

Intervention / Treatment
-----------------
* Drug: Misoprostol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primipara BS ≤ 4p Gestational week >37 Exclusion Criteria: Multipara Multiples Gestational week <37 BS >4 IUFD Previous uterine surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cytotec<br>orally administrated solution of misoprostol (Cytotec®) | Drug: Misoprostol<br>* Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)<br>* Other names: Cytotec;|
| Experimental: Misodel<br>vaginal slow release misoprostol (Misodel®) | Drug: Misoprostol<br>* Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)<br>* Other names: Cytotec;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cesarean section rate |  | 1 year |
Eating and Physical Activity Patterns of the Population Working in the Uruguayan State Electrical Company.

Study Overview
=================
Brief Summary
-----------------
Stuydy of eatin and physical activity patterns in Uruguayan workers and association with obesity, overweight, and tasks.

Detailed Description
-----------------
A sample of workers from the electrical company will be studies as to eating and physical activity patterns, weight variations, and assigned tasks.

Official Title
-----------------
Eating and Physical Activity Patterns of the Population Working in the Uruguayan State Electrical Company.

Conditions
-----------------
Diet Habit, Weight, Body

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: It will include all the officials who joined the company from January 1, 2010 to December 31, 2017, of whom they are between 18 and 65 years old, and the total was from 1964. Exclusion Criteria: On the other hand, regarding the officials who meet the inclusion criteria, the following exclusion criteria are established. Therefore, those officials who: Do not have a medical check-up at admission and at least one checkup between one year and two years after entering the company Officials who no longer continue to work at the institution at the date of the study. Participants who do not have weight and height recorded in the medical record

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight | weight in kilograms will be taken records and in person from 2010 | 2010 at 2020 | 
| Height | Height in meters will be taken records and in person from 2010 | 2010 at 2020 | 
| Body mass index | body mass index in weight / meters squared | 2010 at 2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diet by 24 hours recall | Diet in investigated with 24 hours recall | 2020 | 
| Diet by frequency of food consumption | Frequency of food consumption semi-qualitative | 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diet, Work related, physical activity
Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction

Study Overview
=================
Brief Summary
-----------------
It is a study that hypothesize that MR/PET can have better information than current CT image study, about the medical or surgical treatment outcome of lung cancer

Detailed Description
-----------------
The investigators analyze tumor size、ADCmean、ADCmin、DCE、SUVmax、SUVmin、etc in MR/PET study，to compare its efficacy with other image studies in tumor malignancy grade, systemic involvement detection, treatment outcome after medical target therapy and treatment outcome after surgery.

Official Title
-----------------
Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment, Outcome, and Prognosis Prediction

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Radiation: MR/PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: > 20 years old. Patients have confirmed lung cancer by histopathological methods (fiber, bronchoscopy, lung biopsy, open chest biopsy, pleural effusion exfoliated cells, sputum exfoliated cells) Patients voluntarily to join this study and signed informed consents. Exclusion Criteria: Any body metal implants (pacemaker implantation, nerve stimulator, vascular stent, aneurysm clip, eye foreign body, the inner metal prosthesis) or artificial heart valves Patients with claustrophobia to MRI examination Patients who are reluctant to comply with follow-up and subsequent examination The other condition that do not meet the inclusion criteria. Pregnancy. Age < 20 years old.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MR/PET<br>hypothesize that MR/PET can have better information than current CT image study | Radiation: MR/PET<br>* MR/PET with contrast media and FDG-18<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline PET/MR parameters at 2 months after treatment |  | 2 months after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MR/PET, Non-small cell lung cancer (NSCLC)